OTCMKTS:NUOTQ

(NUOTQ) (NUOTQ) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.0120
$0.0120
50-Day Range
N/A
52-Week Range
$0.00
$0.29
Volume
N/A
Average Volume
304,122 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About (NUOTQ)

Nuo Therapeutics, Inc., formerly Cytomedix, Inc., is a regenerative therapies company developing and marketing products within the United States and internationally through its strategic partners. The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company's commercial offerings are centered on its point of care platform technologies for the separation of blood and bone marrow to produce platelet based therapies or cell concentrates. It is promoting two distinct platelet rich plasma (PRP) technologies: the Aurix System for wound care, and the Angel concentrated Platelet Rich Plasma (cPRP) System for orthopedics and cardiovascular markets. The Company is focused on developing product candidates utilizing the Bright Cell technology platform, owned by its subsidiary, Aldagen, Inc.

NUOTQ Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com
Receive NUOTQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (NUOTQ) and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
OTCMKTS:NUOTQ
Previous Symbol
OTCMKTS:CMXI
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • David Emerson Jorden CPA (Age 52)
    Chief Executive Officer, Chief Financial Officer, Director
  • Peter A. Clausen Ph.D. (Age 49)
    Chief Science Officer
  • Shaun C Martin
    Chief Restructuring Officer
  • Lawrence Atinsky
    Director
  • Paul D. Mintz M.D.
    Director
  • Lyle A. Hohnke Ph.D. (Age 72)
    Independent Director
  • Mark T. McLoughlin (Age 61)
    Independent Director
  • C. Eric Winzer (Age 58)
    Independent Director

This page (OTCMKTS:NUOTQ) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners